FDA for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults. Eplontersen was previously approved for the
The FDA has approved vutrisiran (Amvuttra), patisiran (Onpattro), inotersen (Tegsedi), and eplontersen (Wainua) for treatment of polyneuropathy
Decem - AstraZeneca and Ionis announced the FDA approval of Wainua (eplontersen), for the treatment of the polyneuropathy of
In December 2024, the FDA approved eplontersen, a ligand conjugated antisense oligonucleotide, as a treatment for patients with ATTRv-PN.
The FDA has granted regulatory approval for WAINUA for the Wainua (eplontersen; Ionis, Astrazeneca) is currently the only approved
The FDA has approved eplontersen (Wainua) to treat hereditary transthyretin-mediated amyloidosis (hATTR)-associated polyneuropathy.
The United States Food and Drug Administration (FDA) has approved AstraZeneca and Ionis' Wainua (eplontersen) for treating polyneuropathy of
FDA approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Eplontersen
WAINUA (eplontersen) Approved in US for Adult Polyneuropathy in Hereditary Transthyretin Amyloidosis In the United States, the FDA has
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.